Search Results

Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval in Hong Kong by the Hong Kong Patent Office

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, announced the execution of a territory exclusive distribution agreement in Hong Kong and Macau.

Shanghai Junshi Biosciences Co., Ltd announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region has recently accepted the New Drug Application for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

Sol-Gel Technologies, Ltd. announced that it has signed an asset purchase agreement with Chinese based Shenzhen Beimei Pharmaceutical Co. Ltd, for the commercialization of TWYNEO, for the treatment of acne vulgaris, in the mainland of China, Hong Kong, Macau, Taiwan and Israel.

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia.

HUTCHMED Limited announces that the marketing approval of ELUNATE® by the Pharmacy and Poisons Board of Hong Kong for the treatment of adult patients with previously treated metastatic colorectal cancer.